Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2022-02-08 00:00:00 ET · period of report 2022-02-04 · accession 0001209191-22-007909 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-02-08 | 2022-02-04 | RXRX | Gibson Christopher | CEO, Dir | A - Grant | $0.00 | +210.9K | 234.4K | +899% | $0 |
| D | 2022-02-08 | 2022-02-04 | RXRX | Gibson Christopher | CEO, Dir | F - Tax | $11.40 | -343 | 234.0K | -0.1% | -$3,910 |
| DM | 2022-02-08 | 2022-02-04 | RXRX | Gibson Christopher | CEO, Dir | A - Grant | $0.00 | +421.8K | 5,436 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2022-02-04 | A | A | 208,175 | $0.00 | 231,645 | D | — | — | |
| 2 | Common | Class A Common Stock | 2022-02-04 | F | D | 343 | $11.40 | 234,020 | D | — | — | |
| 3 | Common | Class A Common Stock | 2022-02-04 | A | A | 2,718 | $0.00 | 234,363 | D | — | — | |
| 4 | Derivative | Stock Option (Right to Buy) | 2022-02-04 | A | A | 416,350 | $0.00 | 416,350 | D | $11.40 · — to 2032-02-04 | 416,350 Class A Common Stock | (F3) The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. |
| 5 | Derivative | Stock Option (Right to Buy) | 2022-02-04 | A | A | 5,436 | $0.00 | 5,436 | D | $11.40 · 2022-02-04 to 2032-02-04 | 5,436 Class A Common Stock |